Formulation and optimization of solid lipid nanoparticles of buspirone HCl for enhancement of its oral bioavailability

Journal of Liposome Research

Volumn 20, Issue 4, 2010, Pages 286-296

  Varshosaz, Jaleh ^a   Tabbakhian, Majid ^a   Mohammadi, Mahboobeh Y ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Buspirone HCl; Enhanced bioavailability; First pass effect; Solid lipid nanoparticles

Indexed keywords

ACETONE; BUSPIRONE; DICHLOROMETHANE; HEXADECANOL; PHOSPHATIDYLCHOLINE; SOLID LIPID NANOPARTICLE; SURFACTANT;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUTION; DRUG SYNTHESIS; EXPERIMENTAL DESIGN; IN VITRO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; ORTHOGONAL ROTATION; PARTICLE SIZE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RAT; RESPONSE SURFACE METHOD; TIME TO MAXIMUM PLASMA CONCENTRATION; ZETA POTENTIAL;

ADMINISTRATION, ORAL; ANIMALS; BIOCOMPATIBLE MATERIALS; BIOLOGICAL AVAILABILITY; BUSPIRONE; LIPIDS; MALE; MATERIALS TESTING; NANOPARTICLES; PARTICLE SIZE; RATS; RATS, WISTAR; SEROTONIN RECEPTOR AGONISTS;

EID: 78049467754     PISSN: 08982104     EISSN: 15322394     Source Type: Journal    
DOI: 10.3109/08982100903443065     Document Type: Article

References (34)

1. Al-Khalili, M., Meidan, V. M., Michniak, B. (2003). Iontophoretic transdermal delivery of buspirone hydrochloride in hairless mouse skin. AAPS PharmSci 5:article 14.
2. Bargoni, A., Cavalli, R., Caputo, O., Fundaro, A., Gasco, M. R., Zara, G. P. (1998). Solid lipid nanoparticles in lymph and plasma after duodenal administration to rats. Pharm Res 15:745-750.
3. Bekerman, T., Golenser, J., Domb, A. (2004). Cyclosporin nanoparticulate lipospheres for oral administration. J Pharm Sci 93:1264-1270.
4. Bihari, P., Vippola, M., Schultes, S., Praetner, M., Khandoga, A. G., Reichel, C. A., et al.. (2008) Optimized dispersion of nanoparticles for biological in vitro and in vivo studies. Part Fibre Toxicol 5:14-28.
5. Box, G. E. P., Behnken, D. W. (1960). Some new three level designs for the study of quantitative variables. Technometrics 2:455-475.
6. Caliph, S. M., Charman, W. N., Porter, C. J. (2000). Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and noncannulated rats. J Pharm Sci 89:1073-1084.
7. Cavalli, R., Bargoni, A., Podio, V., Muntoni, E. (2003). Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin. J Pharm Sci 92:1085-1094.
8. Demirel, M., Yazan, Y., Müller, R. H., Kiliç, F., Bozan, B. (2001). Formulation and in vitro-in vivo evaluation of piribedil solid lipid micro- and nanoparticles. J Microencapsul 18:359-371.
9. Desai, M. P., Labhasetwar, V., Amidon, G. L., Levy, R. J. (1996). Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res 13:838-845.
10. Dingler, A., Runge, S., Müller, R. H. (1996). SLN (solid lipid nanoparticles) as drug carrier for an IV administration of poorly water soluble drugs. Eur J Pharm Sci 4:132S.
11. Ferreira, SL., Bruns, RE., Ferreira, HS., Matos, GD., David, JM., Brandão, GC., da Silva, EG., Portugal, LA., dos Reis, PS., Souza, AS., dos Santos, WN. (2007). Box-Behnken design: an alternative for the optimization of analytical methods. Anal Chim Acta 597(2):179-86.
12. Foroutan, S. M., Zarghi, A., Shafaati, A. R., Khoddam, A. (2004). Simple high-performance liquid chromatographic determination of buspirone in human plasma. Farmaco 59:739-742.
13. Govender, S., Pillay, V., Chetty, D. J., Essack, S. Y., Dangor, C. M., Govender, T. (2005). Optimisation and characterisation of bioadhesive controlled release tetracycline microspheres. Int J Pharm 306(1-2):24-40.
14. Holm, R., Müllertz, A., Christensen, E., Høy, C. E., Kristensen, H. G. (2001). Comparison of total oral bioavailability and the lymphatic transport of halofantrine from three different unsaturated triglycerides in lymph-cannulated conscious rats. Eur J Pharm Sci 14:331-337.
15. Humberstone, A. J., Charman, W. N. (1997). Lipid-based vehicles for the oral delivery of poorly water soluble drugs. Adv Drug Deliv Rev 25:103-128.
16. Kim, J. K., Park, J. S., Kim, C. K. (2010). Development of a binary lipid formulation of itraconazole for parenteral administration and controlled release. Int J Pharm 383(1-2): 209-215.
17. Kumar, V. V., Chandrasekar, D., Ramakrishna, S., Kishan, V., Rao, Y. M., Diwan, P. V. (2007). Development and evaluation of nitrendipine loaded solid lipid nanoparticles: influence of wax and glyceride lipids on plasma pharmacokinetics. Int J Pharm 335(1-2):167-175.
18. Luo, Y., Chen, D., Ren, L., Zhao, X., Qin, J. (2006). Solid lipid nanoparticles for enhancing vinpocetines oral bioavailability. J Contr Rel 114:53-59.
19. Manjunath, K., Venkateswarlu, V. (2005). Pharmacokinetics, tissue distribution, and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Contr Rel 107:215-228.
20. Müller, R. H., Mäder, K., Gohla, S. (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm 50:161-177.
21. Murakami, H., Kawashima, Y., Niwa, T., Hino, T. (1997). Influence of the degrees of hydrolyzation and polymerization of poly(vinylalcohol) on the preparation and properties of poly(DL-lactide-coglycolide) nanoparticle. Int J Pharm 149:43-49.
22. Nishimukai, M., Hara, H., Aoyama, Y. (2003). Enteral administration of soybean lecithin enhanced lymphatic absorption of triacylglycerol in rats. Br J Nutr 90:565-571.
23. Paliwal, R., Rai, S., Vaidya, B., Khatri, K., Goyal, AK., Mishra, N., Mehta, A., Vyas, SP. (2009). Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery. Nanomedicine, 5(2):184-191.
24. Schwarz, C., Mehnert, W. J., Lucks, S., Müller, R. H. (1994). Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization, and sterilization. J Contr Rel 30: 83-96.
25. Seeballuck, F., Ashford, M. B., ODriscoll, C. M. (2003). The effects of Pluronic® block copolymers and Cremophor® EL on intestinal lipoprotein processing and the potential link with P-glycoprotein in Caco-2 cells. Pharm Res 20:1085-1092.
26. Sis, H., Birinci, M. (2009). Effect of nonionic and ionic surfactants on zeta potential and dispersion properties of carbon black powders. Coll Surf A Physicochem Eng Asp 341(1-3):60-67.
27. Takka, S., Sakr, A., Goldberg, A. (2003). Development and validation of an in vitro-in vivo correlation for buspirone hydrochloride extended release tablets. J Contr Rel 88:147-157.
28. Varshosaz, J., Soheili, M. (2008). Production and in vitro characterization of lisinopril-loaded nanoparticles for the treatment of restenosis in stented coronary arteries. J Microencapsul 25:478-486.
29. Varshosaz, J., Minayian, M., Moazen, E. (in press). Enhancement of oral bioavailability of pentoxifylline by solid lipid nanoparticles. J Liposome Res
30. Venkateswarlu, V, Manjunath, K. (2004). Preparation, characterization, and in vitro release kinetics of clozapine solid lipid nanoparticles. J Contr Rel 95:627-638.
31. Wissing, A., Kayser, O., Müller, R. H. (2004). Solid lipid anoparticles for parenteral drug delivery. Adv Drug Deliv Rev 56:1257-1272.
32. Yang, S. C., Zhu, J. B. (2002). Preparation and characterization of camptothecin solid lipid nanoparticles. Drug Dev Ind Pharm 28:265-274.
33. Yuan, H., Chen, J., Du, Y. Z., Hu, F. Q., Zeng, S., Zhao, H. L. (2007). Studies on oral absorption of stearic acid SLN by a novel fluorometric method. Coll Surf B Biointerf 58:157-164.
34. Zhang, H., Yao, M., Morrison, R. A., Chong, S. (2003). Commonly used surfactant, Tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats. Arch Pharm Res 26:768-772.